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Mucolipidosis type IV (MLIV) is an autosomal recessive lysosomal storage disorder caused by mutations in the MCOLN1
gene, which encodes the 65-kDa protein mucolipin-1. The most common clinical features of patients with MLIV include
severe mental retardation, delayed motor milestones, ophthalmologic abnormalities, constitutive achlorhydria, and el-
evated plasma gastrin levels. Here, we describe the first murine model for MLIV, which accurately replicates the phenotype
of patients with MLIV. The Mcoln15/5 mice present with numerous dense inclusion bodies in all cell types in brain and
particularly in neurons, elevated plasma gastrin, vacuolization in parietal cells, and retinal degeneration. Neurobehavioral
assessments, including analysis of gait and clasping, confirm the presence of a neurological defect. Gait deficits progress
to complete hind-limb paralysis and death at age ∼8 mo. The Mcoln15/5 mice are born in Mendelian ratios, and both
male and female Mcoln15/5 mice are fertile and can breed to produce progeny. The creation of the first murine model
for human MLIV provides an excellent system for elucidating disease pathogenesis. In addition, this model provides an
invaluable resource for testing treatment strategies and potential therapies aimed at preventing or ameliorating the
abnormal lysosomal storage in this devastating neurological disorder.
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Mucolipidosis type IV (MLIV [MIM 252650]) belongs to a
group of inherited metabolic diseases known as the ly-
sosomal storage disorders (LSDs). It was first described in
1974 as a new variant of the mucolipidoses that displayed
corneal clouding and abnormal systemic storage bodies.1,2
MLIV is a progressive neurological disease that presents
during the 1st year of life with mental retardation, corneal
opacities, elevated blood gastrin levels with achlorhydria,
and delayed motor milestones.1,3 Biochemical studies
demonstrated abnormal storage of sphingolipids, phos-
pholipids, and acid mucopolysaccharides in the lysosomes
of patients with MLIV.4 MLIV is a rare disorder, and the
majority of patients reported to date are of Ashkenazi
Jewish (AJ) descent.5 The MLIV disease gene, MCOLN1
(GenBank accession number NM_020533), maps to chro-
mosome 19p13.2-13.3 and encodes a 580-aa protein with
a predicted molecular weight of 65 kDa, named “muco-
lipin-1” (TRPML1). Structural analysis of the amino acid
sequence predicts that the protein has six transmembrane
domains, and a comparison of the protein sequence
against known protein motifs identified a transient recep-
tor potential (TRP) cation-channel domain and an internal
channel pore. This TRP domain spans transmembrane do-
mains 3–6, with the pore-forming loop between the fifth
and sixth domains.5–8 The major AJ mutation, present on
72% of the AJ MLIV alleles, is an ArG transition at the 3′
acceptor site of intron 3.9 The minor AJ mutation, found
on 23% of the AJ MLIV alleles, is a 6,434-bp genomic
deletion that spans exons 1–6 and the first 12 bp of exon
7.10,11 Discovery of the disease gene has led to the suc-
cessful implementation of genetic screening for MLIV in
the AJ population.10,12 To date, 120 independent mutations
have been described in MCOLN1.11,13–15
Lipid storage disorders are most often caused by defec-
tive lysosomal hydrolases or activator proteins. However,
studies performed before the cloning of the MCOLN1 gene
suggested that MLIV was more likely the result of a defect
in sorting and transport pathways, rather than a degra-
dation defect, since it had been shown that the lysosomal
hydrolases involved in the catabolism of the stored ma-
terial in MLIV were normal.16,17 Lysosomal storage occurs
in cells from every tissue and organ of patients with
MLIV.4,16–21 The composition of the stored material varies
from tissue to tissue,21 is heterogeneous, and includes
sphingolipids (mostly gangliosides), phospholipids, and
acid mucopolysaccharides. Experiments in cultured fibro-
blasts suggested that phospholipids and gangliosides ac-
cumulate in MLIV because of a defect in the process of
endocytosis of membranous components. The defect ap-
pears to lead to excessive transport of these macromole-
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cules into the lysosomes, which is consistent with the
heterogeneity of the stored materials in MLIV.16 Further
studies examined movement of a lipid analogue along the
lysosomal pathway and implicated a defect in the late
steps of the endocytic pathway.17
Numerous studies of TRPML1 function have been per-
formed since it was implicated in MLIV; however, the pre-
cise pathogenic mechanism that leads to disease remains
to be elucidated. TRPML1 belongs to the TRPML family,
which also includes the closely related proteins mucoli-
pin-2 (TRPML2) and mucolipin-3 (TRPML3).5 The TRP su-
perfamily consists of a diverse group of Ca2-permeable
nonselective cation channels that bear structural similar-
ities to the Drosophila melanogaster TRP gene. To date, 120
TRP-related channels have been identified, and they play
roles in extremely diverse cellular processes.22,23 TRP pro-
teins are widely expressed in the nervous system, and, in
nonexcitable cells, these channels may be the primary
mode of calcium entry. TRPML1 was initially reported as
a novel nonselective cation channel that was permeable
to Ca2 and was regulated by changes in Ca2 concentra-
tion.24 Subsequent studies performed in endosomal vesi-
cles from MLIV cells, as well as in liposomes containing
the in vitro translated protein, suggested that the channel
can be inhibited by pH reduction and Ca2 transport.25,26
Recently, demonstration of a strong outwardly rectifying
current in whole-cell recordings has led to the suggestion
that TRPML1 might function to regulate lysosomal pH and
to maintain the required acidity for normal lysosomal hy-
drolase function.27,28 Several studies have shown that
TRPML1 is localized to late endosomes and lysosomes.29–31
An N-terminal dileucine motif is sufficient for lysosomal
targeting of full-length TRPML1, and this targeting is AP1
dependent.9,31,32 Endogenous TRPML1 is cleaved in its long
luminal loop between the first and second transmembrane
domains; however, the role of this cleavage in regulating
protein function has yet to be determined.31,33 Homo- and
heteromultimerization of TRPML1 with TRPML2 and
TRPML3 was recently described in cells overexpressing all
three proteins.32 Significant mitochondrial fragmentation
and decreased mitochondrial Ca2 buffering efficiency
have also been described in MLIV cells. Jennings et al.
speculate that a defect in mitochondrial recycling leads to
increased sensitivity to apoptosis induced by Ca2, pos-
sibly explaining the degenerative cell death found in MLIV
and other LSDs.34 Defective lysosomal exocytosis has also
been reported in fibroblasts isolated from patients with
MLIV.35
The Caenorhabditis elegans mucolipin-1 gene ortholog,
cup-5, was isolated during a screen for endocytosis-defec-
tive mutants.36 Mutations in cup-5 result in an enhanced
rate of uptake of fluid-phase markers, decreased degra-
dation of endocytosed protein, and accumulation of large
vacuoles. Interestingly, human TRPML1 was able to rescue
the abnormal lysosomal accumulation in these mutants.
Recent studies in C. elegans revealed that a mutation in
the ATP-binding cassette transporter MRP-4 compensates
the degradation defect caused by the absence of cup-5.37
The phenotype of MLIV is variable, with psychomotor
delay and corneal opacities by age 1 year as the most com-
mon presentation.21,38 The brain pathology in patients
with MLIV is characterized by pigmented cytoplasmic
granules in nondistended neurons and microglial cells.21
Electron microscopy (EM) reveals accumulation of lam-
ellated membrane structures and amorphous material in
lysosomes in every cell type examined.21,38 Cultured skin
fibroblasts derived from patients with MLIV contain au-
tofluorescent lysosomes.39 Storage vacuoles are present in
the corneal epithelium, as well as in many other cell types,
including pancreatic acinar cells, macrophages, and chon-
drocytes, and in the renal collecting ducts and hepatic bile
duct.38,40 Diagnosis of MLIV is suggested for patients with
characteristic neurodevelopmental delay, elevated blood
gastrin levels, and corneal clouding. Currently, confir-
matory molecular diagnosis can be made via targeted mu-
tation analysis of the two most common mutations, IVS3-
2 ArG and 511r6994 del, which together account for 95%
of mutations in the AJ population.10
To understand the pathogenic mechanism by which
complete loss of TRPML1 causes MLIV, we generated a
mouse with a targeted disruption of the Mcoln1 gene
(GenBank accession number NM_053177). This Mcoln1
knockout, designated “Mcoln1/,” exhibits many clinical
and cellular features of the human disease. Murine Mcoln1
is highly similar to human MCOLN1, showing 86% nu-
cleotide identity and 91% amino acid identity. In addition,
all six of the transmembrane domains, the putative cation
channel, and the dileucine (L-L-X-X) motif at the C-ter-
minus are all highly conserved.41 Our mouse model will
be an invaluable resource for understanding the role of
TRPML1 in lysosomal function and vesicular trafficking,
mitochondrial recycling, and other cellular functions that
play a role in the pathophysiology of MLIV. Furthermore,
Mcoln1/ mice will be crucial for testing therapeutic
agents aimed at ameliorating the abnormal lysosomal stor-
age in MLIV.
Material and Methods
The Mcoln1/ knockout mice were generated and propagated fol-
lowing National Institutes of Health (NIH) guidelines for animal
care under an approved protocol of the Animal Care and Use
Committee of the National Institutes of Mental Health. All breed-
ing and other procedures performed were reviewed and approved
by the Massachusetts General Hospital Subcommittee on Re-
search Animal Care.
Generation of Mcoln1/ Mice
Mcoln1 genomic DNA clones were isolated by plaque hybridiza-
tion of a mouse 129/Sv genomic DNA library with full-length
mouse Mcoln1 cDNA probes. The targeting vector was constructed
as follows (fig. 1A): a neomycin resistance gene (Neor cassette)
for positive selection was inserted between exons 2 and 5 of
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Figure 1. Generation of Mcoln1/ knockout mice. A, Illustration of the Mcoln1/ targeting strategy. The top line shows the wild-
type Mcoln1 allele, with restriction-enzyme sites, the locations of exons (blackened boxes), and the locations of 5′ and 3′ genomic DNA
probes (hatched boxes). The second line shows the loxP-flanked PGK-neomycin (PGK-Neo) cassette–targeting vector, with upstream and
downstream Mcoln1 genomic DNA. The HSV-TK cassette was inserted at the 3′ end of the construct, for negative selection. exp exon;
KO p knockout. The third line shows the configuration of the properly targeted allele (Mcoln1ex3,4/5neo) created by homologous recom-
bination in embryonic stem cells. Restriction-enzyme sites are EcoRI (E), BamH1 (B), SalI (S), and NotI (N). B, Southern-blot analysis
of embryonic stem cell clone DNA with the 5′ probe. Genomic DNA isolated from embryonic stem cell clones was digested with AseI.
The 5′ probe detects the wild-type (11.2-kb) and targeted (7.7-kb) bands in Mcoln1/ (lanes 2 and 6) and Mcoln1/ (lanes 3 to 5)
mice. C, Mouse genotyping by analysis of ethidium bromide–stained PCR products from DNA obtained from tail snips. Mcoln1/ and
Mcoln1/ mice present only a single band of 400 bp and 187 bp, respectively; Mcoln1/ mice present both bands. D, Ethidium bromide–
stained RT-PCR products were amplified from Mcoln1/ and Mcoln1/ brains by use of Mcoln1 exon 2 forward primer and exon 6 reverse
primer. DNA sequencing confirmed the identity of the Mcoln1 band.
Mcoln1. The herpes simplex virus–thymidine kinase gene (HSV-
TK) for negative selection was inserted 3′ of Mcoln1 within exon
13. Methods for generating targeted embryonic stem cells and
producing mice from these cells have been described elsewhere.42
Hybrid LC3 (C57BL6#129S6) embryonic stem cells (GlobalStem)
were transfected with the Mcoln1 targeting vector by electropor-
ation. After 24 h, cells were fed with medium containing 200 mg/
ml of G418. G418-resistant clones were picked after 7 d and were
screened for homologous recombination by Southern blotting.
Three clones carrying a Mcoln-1 targeted allele were injected into
C57BL6 blastocysts, which were then transferred into oviducts
or uterus of pseudopregnant outbreed recipient females. Pups
were evaluated for chimerism. Chimeras from all three lines were
mated to C57BL/6 females. Germline transmission was evidenced
by coat color and was confirmed by PCR.
Southern-Blot Analysis
For Southern-blot analysis, 5′ and 3′ probes were generated using
the following sets of primers: forward 5′-TAAACTTGGTGGAGGC-
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TTGC-3′ and reverse 5′-GTGCTCAGCCACTGGGTAAC-3′ and for-
ward 5′-TAGGCTGATCAACGTCACCA-3′ and reverse 5′-GGGTCT-
GAGGATGGGAGAGT-3′. Mouse genomic DNA was used as a tem-
plate for the reactions. DNA extracted from embryonic stem cells
was digested with AseI (for 5′-probe hybridization) and with PinA
and PspI (for 3′-probe hybridization), was run on a 0.8% agarose
gel, was blotted onto GeneScreen Plus membrane (Perkin Elmer),
and was hybridized with the respective radiolabeled probes.
The 5′ probe detected a 7.7-kb band in the targeted allele and an
11.2-kb band in the normal allele, and the 3′ probe detected a
9.6-kb band in the targeted allele and an 11.2-kb band in the
normal allele.
mRNA Expression Analysis
For expression analysis, 1–2 mg of total RNA extracted from brain
was used to synthesize cDNA with SuperScript III (Invitrogen Life
Technologies) and was used as template for PCR and quantitative
real-time PCR (Q-PCR ), as follows. For PCR, exons 2–6 of Mcoln1
were amplified with the primer set forward 5′-CCCCACAGAAGA-
GGAAGA-3′ and reverse 5′-GTGGATGGTGACATTGACC-3′. PCR
products were sequenced to confirm Mcoln1 identity.
For Q-PCR, analysis of Mcoln1 was performed using SYBR Green
PCR kit in I-Cycler (Bio-Rad). Standard curves representing five-
point 1:3 serial dilution of cDNA of one of the samples in the
control group were analyzed in each assay. The values were2r
0.99 for all standard curves, and the amplification efficiency
varied between 90% and 100%. Sample relative quantification
was analyzed by the DCT method, using CT values from Mcoln1
/
mice as calibrators, and was corrected by the internal control—
hypoxanthine guanine phosphoribosyl transferase (HPRT)—in all
experiments. Primers were designed to detect Mcoln1 message
within exon 4 forward primer 5′-ATGTGGACCCAGCCAATGATA-
CCT-3′ and exon 6 reverse primer 5′-TGTCTTCAGCTGGAAGTG-
GATGGT-3′. Mouse HPRT primers were forward 5′-TCGAAGTGTT-
GGATACAGGCC-3′ and reverse 5′-CAACAGGACTCCTCGTAT-
TTG-3′. All primers were designed using PrimerQuest software
(Integrated DNA Technologies).
Genotyping
Genotyping was done by PCR with use of genomic DNA from
mouse tail snips, prepared using the method with hot sodium
hydroxide and Tris-HCl.43 PCR was performed with HotStart-Red
Taq polymerase (Sigma). Three primers were used in the reaction
to easily identify Mcoln1/ (wild-type), Mcoln1/ (heterozygote),
and Mcoln1/ (knockout) mice: forward 5′-GACCCAGGAATGAC-
ACCTTC-3′, located in intron 3 position 9060 of the Mcoln1 se-
quence; reverse 5′-CCCCTTGCTGCCATGTAATA-3′, located in the
Neor cassette present in the targeted allele; and reverse 5′-GCGCA-
AACCACATGTGCTTT-3′, located in intron 3 position 9441 of
Mcoln1.
Histopathological Analysis and EM
Stomach.—Mcoln1/ and Mcoln1/ mice were sacrificed, and
gastric tissues were harvested and washed. The tissues were dis-
sected from mice and were fixed in 2.0% glutaraldehyde in 0.1
M sodium cacodylate buffer (pH 7.4) overnight at 4C. Tissues
were stained with hematoxylin and eosin for light microscopy or
were postfixed in 1.0% osmium tetroxide (Electron Microscopy
Sciences) in cacodylate buffer for EM and infiltrated with Epon
resin (Ted Pella). The following day, samples were placed in fresh
100% EPON resin and were embedded in an oven at 60C over-
night. Thin sections were stained with uranyl acetate and lead
citrate and were examined at 80 kV in a JEOL 1011 transmission
electron microscope (Advanced Microscopy Techniques).
Brain.—For studies of brain, mice were deeply anesthetized with
sodium pentobarbital and were perfused systemically with 0.9%
saline followed by 4.0% paraformaldehyde in 0.1 M phosphate
buffer. Tissue blocks for EM were postfixed in 2.5% glutaraldehyde
in 0.1 M cacodylate buffer. Before the embedding in EPON, tissues
were fixed in 2% osmium tetroxide, were dehydrated in alcohols,
and were plastic embedded. Ultrathin sections were cut on an
ultramicrotome, were stained with uranyl acetate and lead citrate,
and were examined on a Philips CM10 electron microscope.
LAMP2 staining of cerebrocortical neurons was done with im-
munoperoxidase according to the protocol previously described
by Zervas et al.44
Eyes.—Eyes were enucleated immediately after sacrifice, and the
globe was cleaned of all extraneous tissue and then was rinsed
with saline. The globe was immediately placed into fixative con-
sisting of 2.5% gluteraldehyde and 2% formaldehyde in 0.1 M
cacodylate buffer with 0.08 M CaCl2 at 4C. After a short 10–15-
min fixation, the eye was bisected at the limbus, the anterior
segment was separated from the posterior segment, and the parts
to be examined were placed back in the fixative. Within 24 h
after enucleation, the tissue was washed in 0.1 M cacodylate
buffer and was stored at 4C. The tissue was postfixed for 1.5 h
in 2% aqueous osmium tetroxide. Tissue was dehydrated in
graded ethanol, was transitioned in propylene oxide, was infil-
trated with propylene oxide and EPON mixtures (TAAB 812 resin
[Marivac]) embedded in EPON, and was cured for 48 h at 60C.
Sections of 1 mm were cut on a Leica Ultracut UCT and were
stained with 1% toluidine blue in 1% borate buffer. For EM, thin
sections were cut and were stained with saturated, aqueous uranyl
acetate and Sato’s lead stain. Examination was done on a Philips
CM10 electron microscope.
Radioimmunoassay for Gastrin
Plasma samples from Mcoln1/ and Mcoln1/mice were obtained
from the abdominal aorta before death. Gastrin concentrations
for total amidated gastrin concentrations were determined by ra-
dioimmunoassay with use of L2 antibody (which reacts with G17
and G34 but not with progastrin or Gly-gastrins) to the COOH
terminus of amidated gastrin, as described elsewhere.45 Standard
curves were prepared using human G17 as a standard in hor-
mone-free plasma, and samples were diluted to fall in the mid-
range of the standard curve.
Behavioral Analyses
Studies were performed in Mcoln1/ and Mcoln1/ littermates.
Animals were analyzed for clasping, gait, and overall behavior
and appearance. Clasping analysis was done by grasping the tail
and holding the mouse 12 in from a solid surface for 30 s. The
test was considered positive for clasping if limbs were clenched
toward the belly for ∼5 s. Gait analysis was done by placing each
animal with differentially painted hind paws and forepaws in a
paper-lined tunnel apparatus. Measurements of the stride length
(rear paw–to–rear paw distance) and base width (rear-paw stance)
were determined. Overall behavior assessment was done on the
basis of the first phase of the Behavior Primary Screen (SHIRPA
protocol), with modifications.46 In brief, each mouse was indi-
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Figure 2. Survival rates in Mcoln1/ mice ( ) versusnp 12
Mcoln1/ mice ( ). Results are expressed as the percentagenp 9
of live animals plotted against age, ranging from 0 to 10 mo.
Mcoln1/ animals were all severely paralyzed at ages 7–9 mo and
were euthanized.
vidually placed in a viewing jar for 5 min, and body position,
spontaneous activity, respiration rate, and posture were moni-
tored and recorded without disturbing the animal. All behavior
studies were repeated two times for each mouse, on two separate
days by two investigators blinded to the phenotype of the ani-
mals. Statistical significance was tested with one-way analysis of
variance (ANOVA).
Results
Generation of Mcoln1/ Mice
We have generated a strain of mice with a targeted dis-
ruption in the Mcoln1 gene. The knockout construct was
generated by replacing exons 3 and 4 and 72 bp of exon
5 of Mcoln1 with a PGK-neomycin cassette (fig. 1A). Be-
cause the deletion leads to a frameshift in exon 5, the
Mcoln1 knockout allele was expected to be null. Homol-
ogous recombination in embryonic stem cells was con-
firmed by genomic Southern-blot analysis, and analysis
revealed the expected restriction fragments, confirming
proper targeting (fig. 1B). We identified three positive em-
bryonic stem cell clones from 200 mg/ml of G418. Three
correctly targeted embryonic stem cell clones were mi-
croinjected into B6 blastocysts to generate chimeras. The
chimeras were crossed with B6 mice to establish and main-
tain the Mcoln1 heterozygous (Mcoln1/) mouse line on
a mixed 129/B6 hybrid background. Homozygous mice
(Mcoln1/) were obtained from heterozygote breeding and
were genotyped (fig. 1C). No phenotypic differences were
ever observed in mice generated from the three targeted
ES clones. We confirmed the absence of Mcoln1 transcripts
in Mcoln1/ mice, using RT-PCR of brain cDNA (fig. 1D).
cDNA generated from Mcoln1/ and Mcoln1/ brains was
analyzed by Q-PCR with specific primers for Mcoln1,
which also confirmed the absence of Mcoln1 message in
Mcoln1/ mice (data not shown).
Progressive Hind-Limb Paralysis and Decreased Life Span
of Mcoln1/ Mice
At birth, affected pups were indistinguishable from litter-
mates. Therefore, nine Mcoln1/ mice were observed as
they aged. At age 3 mo, there were no obvious differences
in growth, appearance, or behavior. Open field tests
showed no difference in activity or distance covered, and
growth rate and weight were as-yet indistinguishable be-
tween Mcoln1/ animals and wild-type littermates. How-
ever, when strength was assessed in the hanging wire
test,47 3-mo-old Mcoln1/ mice had lost strength, com-
pared with 2-mo-old Mcoln1/ or 3-mo-old Mcoln1/ lit-
termates (data not shown). At age 6 mo, the mice began
to show lethargy, compared with their Mcoln1/ and
Mcoln1/ littermates. At age ∼6.5 mo, we began to detect
noticeable gait changes, which quickly progressed to total
hind-limb paralysis and death. The age at onset of the
noticeable changes in motor behavior was variable, with
the earliest animal showing onset at age ∼6.5 mo and two
animals showing onset at age 8.5 mo. Regardless of onset
age, the progression was similar, with 3–4 wk from onset
to complete hind-limb paralysis and sacrifice. Survival
rates were statistically different for Mcoln1/ mice, with
an average age at death of 8 mo (fig. 2).
We performed gait and clasping studies in Mcoln1/ and
Mcoln1/ animals of matched ages, in the range 6–9 mo.
Studies were performed before onset of visible paralysis.
Clasping studies done in two separate trials ( , eachnp 8
mouse tested twice) revealed clasping in 94% of the
Mcoln1/ tests as compared with clasping in only 19% of
the Mcoln1/ tests (fig. 3A). Hind-paw and forepaw gait
measurements during tunnel walks revealed significantly
shortened average stride length (rear paw–to–rear paw dis-
tance) for Mcoln1/ mice ( cm for Mcoln1/ vs.5.96 0.9
cm for Mcoln1/; ), and no statistical3.98 0.2 P ! .0001
difference was observed in base width (rear-paw stance)
(fig. 3B and 3C). Notable differences were observed in total
body weight at the time of testing ( g for35.66 6.80
Mcoln1/ vs. g for Mcoln1/; ) (fig.24.62 3.84 P ! .0001
3D). This seems to be caused by loss of subcutaneous fat
and decreased muscle mass, despite food and sterile water
gel being readily available in the bottom of the cages.
Other behavioral assessments, including body position,
respiration rates, spontaneous activity, and posturing,
were compared, and results were not statistically different.
Clinical manifestations of the gait deficiency progressed
until the Mcoln1/ mice showed dragging of the hind
limbs, severely hunched posture, abdominal distension,
and scruffy coat (fig. 4A). Three Mcoln1/ mice showing
marked paralysis at ages 7–9 mo were sacrificed, as were
three age-matched Mcoln1/ controls, for anatomical ex-
amination. Brain, heart, and eyes were carefully dissected
and weighed. Although there were no statistical differ-
ences in these tissues between Mcoln1/ and Mcoln1/
mice, cardiac anatomy suggested a subtle dilated cardio-
myopathy, and the Mcoln1/ brains were slightly smaller.
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Figure 3. Neurologic deficits and decreased body weight in Mcoln1/ mice. A, Graph showing dramatically increased clasping in
Mcoln1/ mice aged 7–9 mo. B, Gait analysis. Results expressed as average  SD of stride length in cm (rear paw–rear paw stance)
for Mcoln1/ mice ( ; 180 strides) and Mcoln1/ mice ( ; 192 strides). Base width (rear-paw stance) was also measured,np 8 np 8
but no significant difference was detected. C, Gait analysis shown by footprints. Footprints are represented in blue (front paws) and
red (hind paws). The Mcoln1/ mouse has a stride length of 6 cm at age 7–9 mo, whereas the Mcoln1/ mouse has stride length of
4.5 cm. D, Total body weight in Mcoln1/ versus Mcoln1/. Results are expressed as average  SD of Mcoln1/ mice ( ) andnp 9
Mcoln1/ mice ( ). Statistical significance was assessed by one-way ANOVA.np 15
Both of these observations will require further investiga-
tion at a variety of ages to determine the cause and extent
of the pathology. At the time of sacrifice, the Mcoln1/
mice exhibited a grossly distended bladder filled with 1–
2 ml of turbid urine (fig. 4B). The bony architecture of the
severely emaciated Mcoln1/mice was demonstrative, and
the ribs and spine can be clearly seen after skin removal.
The Mcoln1/ physical examination revealed loss of major
muscle bulk, absence of subcutaneous fat stores, and
decreased overall weight measurements, despite similar
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Figure 4. Anatomical differences in Mcoln1/ animals. A, Com-
parison of Mcoln1/ and Mcoln1/ littermates, showing complete
hind-limb paralysis in Mcoln1/ mice. B, Dramatically distended
bladder, seen in all Mcoln1/ mice at age 8 mo. C and D, Com-
parison of Mcoln1/ and Mcoln1/ mice after removal of skin,
showing loss of major muscle bulk and absence of subcutaneous
fat stores.
length measurements between the Mcoln1/ and Mcoln1/
groups (fig. 4C). Similar decreased muscle mass and fat
storage was noted in hind-limb dissection (fig. 4D).
CNS Inclusion Formation in Mcoln1/ Mice
To evaluate inclusion-body formation in Mcoln1/ mice,
we investigated CNS tissues of Mcoln1/ mice and litter-
mates at age 8 mo. Ultrastructural studies in murine MLIV
disease revealed inclusions in neurons, astrocytes, oligo-
dendroglia, microglia, and endothelial cells. Some neu-
rons contained large numbers of inclusions, mostly con-
fined to the basilar cytoplasm, as shown in the large
pyramidal neuron (fig. 5A). The inclusions closely resem-
bled what were referred to in an earlier study of MLIV in
a 7-year-old child as “compound bodies.”38 That is, they
consisted of an unusual intermixture of compact lamellae
and a granular matrix, with the latter occasionally pre-
senting as a crystalline array (fig. 5B and 5C). At times,
the inclusions formed as a large commingled mass con-
centrated within localized regions of the neuronal peri-
karyon. Purkinje neurons in the cerebellum exhibited in-
clusions that were very similar to cortical pyramidal
neurons. Generally, neurons appeared to exhibit more in-
clusions than did glial cells. Inclusions in oligodendroglia
in the cerebral cortex were similar to those in neurons but
often possessed a more open, swirling pattern of compact
lamellae (fig. 5D). Inclusions in astrocytes also typically
resembled those seen in neurons but were observed only
occasionally (fig. 5E). Microglial inclusions were often nu-
merous and possessed densely packed sheets of lamellae
intermixed with granular matrixes (data not shown). To
confirm the lysosomal identity of the storage vesicles, we
performed LAMP2 staining with peroxidase, which dem-
onstrated the increased number and size of LAMP2-posi-
tive vesicles in Mcoln1/ neurons (fig. 5F–5I). Overall, the
ultrastructure of the inclusions observed in Mcoln1/mice
match what has been described in human MLIV. The MLIV
inclusions are unusual in terms of the combination of
dense lamella and granular matrices, and, as such, they
do not resemble those typically seen in the glycosphin-
golipidoses, the mucopolysaccharidoses, or most other
types of lysosomal disease.
Gastric Pathology of Mcoln1/ Mice
Patients with MLIV are constitutively achlorhydric as a
result of a block in gastric acid secretion. Parietal cells from
patients with MLIV have very large lysosomes that contain
lamellar, concentric, microgranular inclusions.48 Analysis
of the gastric epithelium of Mcoln1/ mice revealed sim-
ilar dramatic vacuolization (figs. 6 and 7). Examination of
the gross morphology shows extremely large vesicles in
the gastric mucosa (fig. 6B). Vesicles are visible along the
length of the gastric pit (fig. 6D). Overall, the morphology
of the gastric mucosa is not dramatically different in the
Mcoln1/ mice, with only minor reductions in the num-
ber of granular pit cells on the surface and zymogenic cells
in the base of the gastric pit. Ultrastructural examination
shows that, in addition to the large vesicles observed in
parietal cells (fig. 7B), numerous smaller vesicles are also
present in the mucus-producing neck cells (fig. 7C). The
vesicles in both cell types contain storage material, which
is an unusual mixture of compact lamellae and granular
matrix (fig. 7B and 7C). Interestingly, intact vesicles were
observed in the lumen adjacent to the epithelial cells in
the neck region (fig. 7B and 7C), suggesting that the se-
cretory vesicles fail to fuse with the apical membrane of
the gastric epithelium. Although the overall morphology
of the gastric mucosa is not different in the Mcoln1/
mice, minor reductions in the granular pit cells on the
surface and zymogenic cells in the base are seen. However,
the subepithelial mucosa or the gastric muscle layers are
unaffected in the Mcoln1/ mice.
A hallmark of human MLIV is elevated plasma gastrin,48
which can be increased up to 13 times that of normal.
The serum gastrin in Mcoln1/ mice was significantly el-
evated compared with that in Mcoln1/ mice (fig. 8). The
average gastrin level in Mcoln1/ mice was 158.6 pM com-
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Figure 5. CNS lysosomal storage in 8-mo-old Mcoln1/ mice. A, Large cortical pyramidal neuron (based on cell size and morphology),
exhibiting a large cache of granulomembranous storage bodies located principally beneath the nucleus in the base of the perikaryon
(arrow). B and C, Higher magnification view of inclusion bodies in neurons. Note the presence of both membranous lamella and a
granular, dense core matrix. D, An oligodendroglial cell (based on nuclear and cell morphology) exhibiting a few membranous inclusions
at one end of the cell (arrow). E, Astrocyte (based on presence of longitudinal bundles of filaments) containing several inclusions
(arrow) resembling those of neurons. The calibration bar in panel A equals 2.25 mm, whereas it equals 0.65 mm in panel B, 0.30 mm
in panel C, and 1.75 mm in panels D and E. F–I, LAMP2 staining of pyramidal neurons in the cortex from 8-mo-old Mcoln1/ mice (F
and H) and Mcoln1/ mice (G and I). Immunoperoxidase labeling of neurons in Mcoln1/ versus Mcoln1/ cerebral cortex shows
increased number and size of LAMP2-positive vesicles in affected neurons (unblackened arrows). The calibration bar is 10 mm in panels
F and G and is 5 mm in panels in H and I. N p nucleus.
pared with 76.25 pM in age- and sex-matched Mcoln1/
controls ( ). Iron studies, including assays of freePp .0006
iron and total iron-binding capacity, did not reveal
any statistical differences between Mcoln1/ mice and
Mcoln1/ mice (data not shown).
Severe Retinal Degeneration in Mcoln1/ Mice
Patients affected with MLIV have defined corneal cloud-
ing, retinal degeneration with varying degrees of vascular
attenuation, and mild optic-nerve pallor.49 The retinas of
Mcoln1/ mice show significant degeneration, and optic-
nerve pallor was evident by gross histology (fig. 9A and
9B). Mcoln1/ mice have a dystrophic outer nuclear layer
with reduced receptor nuclei and a significantly reduced
outer plexiform and inner nuclear layer, compared with
those of their Mcoln1/ controls. Interestingly, there is no
evidence of corneal clouding by slit-lamp examination by
age ∼7 mo. This finding is corroborated by histological
studies, since there is no discernible difference between
the Mcoln1/ and Mcoln1/ corneal stroma at age 5 mo
in architecture, thickness, or cell morphology (fig. 9C and
9D).
Discussion
In this article, we report the generation and characteri-
zation of the first murine model of the human disease
MLIV. Our initial studies show that this model accurately
replicates many aspects of the human disease. The
Mcoln1/ mouse therefore will be invaluable for future
studies aimed at understanding the role of TRPML1 in
normal lysosomal function, as well as for the development
and testing of potential therapies for MLIV.
The primary genetic defects of most LSDs have been
identified and are known to include not only lysosomal
enzymes but also a host of nonlysosomal enzymes in the
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Figure 6. Morphology of stomach mucosa. A, Representative image of the antral region of the mouse stomach, showing normal gross
morphology of the gastric epithelium. B, Representative image of the antral region of the mouse stomach, showing the gross morphology
of the gastric epithelium of Mcoln1/ mouse. In panels A and B, magnification is 63#. C and D, Detailed morphology of the gastric
glands. Increased frequency of the parietal cells in the neck region of the gastric epithelium was observed in the mutant mice with
enlarged and multiple secretary vacuoles. GP p gastric pit; L p lumen. In panels C and D, magnification is 630#. In all panels,
staining is toluidine blue.
endoplasmic reticulum and Golgi, as well as nonenzyme
proteins of endosomes.50 In spite of this remarkable pro-
gress, numerous uncertainties remain concerning the pre-
cise mechanisms by which many of these protein defects
cause cell injury and disease progression. This is particu-
larly true of newly discovered nonenzyme proteins like
NPC1, NPC2, CLN3, and, as reported here, TRPML1. In
this study, we show that mice lacking TRPML1 exhibit the
presence of dense granulomembranous storage bodies in
neurons and many other cell types that closely resemble
the so-called compound bodies described in human MLIV
disease, a type of inclusion that is not generally seen in
any other type of LSD.38 Although, in some respects, the
granulomembranous storage bodies of MLIV disease re-
sembled the membranous cytoplasmic bodies seen in the
gangliosidoses and the so-called zebra bodies of the mu-
copolysaccharidoses, they also had conspicuous granular
components that were more similar to inclusions de-
scribed in the neuronal ceroid lipofuscinoses (CLN [MIM
204200]).51,52 This finding is compatible with the view that
MLIV disease is characterized by multiple substrate stor-
age, possibly related to a generalized compromise in ly-
sosomal function secondary to alterations in lysosomal
pH. Indeed, it has been suggested recently that MLIV may,
in fact, be caused by chronically acidic lysosomal pH that
results in inactivation of lysosomal lipases.28 It is inter-
esting to note, however, that there is no reported neuronal
storage in a mouse model of Wolman disease (MIM
278000), which lacks functional lysosomal acid lipase,53
suggesting that a lipase defect alone may not account for
the heterogenous storage seen in MLIV. Complicating
things further, the literature also contains reports of nor-
mal30 and elevated lysosomal pH in MLIV.2 The biochem-
ical mechanism behind the storage-body accumulation—
and the resulting effect on cell function—remains to be
determined. We have shown that the storage bodies in the
Mcoln1/ mouse model are identical to those observed in
patients with MLIV; therefore, this model will be helpful
in elucidating the pathways leading to abnormal storage.
The original finding of iron deficiency in patients with
MLIV led to the discovery of elevated blood gastrin cou-
pled with achlorhydria. Subsequent gastroscopy studies
identified distended parietal cells containing large vacu-
oles with lamellar, concentric inclusions.48 The gastric
phenotype observed in the Mcoln1/ mice is remarkably
similar to what has been described in patients with MLIV
and includes both elevated gastrin and cellular vacuoli-
zation.48 Four major types of secretory epithelial cells cover
the surface of the stomach and extend down into the gas-
tric pits and glands. The neck cells secrete thick mucus
that serves as protection against the action of gastric
juices. Parietal cells are located within the gastric pits and
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Figure 7. EM of gastric epithelium. Ultrastructural figures of the
neck region of the gastric epithelium for Mcoln1/ and Mcoln1/
mice are shown. A, Normal gastric epithelium at the neck region
of the Mcoln1/ mice, compared with that of Mcoln1/ mice. B
and C, Parietal (B) and neck (C) cells, both showing a pronounced
defect with multiple enlarged vesicles. Vesicles are retained in
Mcoln1/ epithelium and fail to fuse with the apical surface (un-
blackened arrow), and granular storage material is seen within
vesicles (blackened arrow). In addition to large intact vacuoles
within the cells, vesicles are also observed outside the cells in the
lumen of the stomach. Lp lumen; Np nucleus. In panels B and
C, magnification is 6,000#.
secrete both HCl and intrinsic factor. Gastrin is secreted
by enteroendocrine G cells in the pyloric glands, and chief
cells secrete pepsin, a proteolytic enzyme.54,55 For acid se-
cretion to occur, calcium signaling is required for fusion
of the tubulovesicles to the canalicular membranes. Chan-
nel proteins are known to play critical roles in membrane-
trafficking events, including transport of vesicles and
docking and fusion with cellular membranes, suggesting
a direct role for TRPML1 in acid secretion. Interestingly,
the initial human studies suggested that the large vacuoles
are limited to the parietal cells; however, ultrastructural
examination of the Mcoln1/ mucosa clearly shows vac-
uoles with granular storage material in the mucus-secret-
ing neck cells of the gastric pit. Effective mucus secretion
is required for protection of the stomach mucosa, and
increasing mucosal atrophy with age has been described
in patients with MLIV.48 Given that the Mcoln1/ mice
show decreased subcutaneous fat stores and slightly de-
creased muscle mass at age 7–8 mo, it will be interesting
to determine whether this is due to mucosal atrophy in
older animals. The Mcoln1/ model provides an excellent
system in which to elucidate the role of TRPML1 in acid
and mucus secretion, as well as to study the long-term
physiological effects of mucosal atrophy.
Corneal clouding is a hallmark of human MLIV, and it
is frequently the first defect evident in most patients. In
fact, diagnosis of MLIV is frequently made after ophthal-
mologic examination and conjunctival biopsy. Detailed
corneal examination of several Mcoln1/ mice via slit-
lamp analysis by trained observers did not reveal any cor-
neal clouding by age 7 mo. Further, EM studies failed to
detect any defects in the corneal stroma. This phenotypic
discordance has occurred in several other LSD murine
models, notably those for mucopolysaccharidosis (MPS) I
(MIM 607014),56 MPS IV (MIM 253200),57 and GM1 gan-
gliosidosis (MIM 230500).58,59 Genetic causes of corneal
clouding are variable, and it is often the result of abnormal
function of the corneal endothelium, which disrupts fluid
homeostasis. The mechanism of corneal clouding in LSDs
is also variable and is not completely understood. In many
LSD animal models, direct storage in stromal keratocytes
appears to be the etiology of the clouding, even with a
functional endothelium.60–62 In some LSD mouse models
that are discordant for corneal clouding, histopathological
corneal-architecture differences were noted between af-
fected and wild-type mice, but there was no evidence of
clouding on physical examination.63 The etiology of this
corneal preservation is unclear, but increased genetic func-
tional redundancy in the mouse may be present. In ad-
dition, the composition of proteoglycans in the mouse
corneal stroma is different than that in other mammalian
species, with keratin sulfate predominantly undersulfated
and an overall different immunostaining pattern of chon-
droitin and dermatin sulfates.64 These differences may
contribute to a lower susceptibility to corneal clouding
that depends on the precise molecular mechanism leading
to storage or endothelium dysfunction.
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Figure 8. Significant increase in plasma gastrin in Mcoln1/
mice ( ). The concentration of plasma gastrin was mea-Pp .0006
sured by radioimmunoassay. Mcoln1/ mice ( ) or Mcoln1/np 11
mice ( ) were sacrificed for the collection of plasma andnp 13
tissue samples. The total number of mice ( ), the mean age,np 24
and the numbers of male and female mice were approximately equal
for the Mcoln1/ and Mcoln1/ groups.
Figure 9. Mcoln1/ ocular pathology. A, Toluidine blue–stained cross section of Mcoln1/ mouse retina. B, Mcoln1/ mouse retina.
Note the severe thinning and irregularity of the entire receptor layer (OS/IS) and the dramatic loss of outer nuclear layer (ONL) nuclei.
The structure of the retinal pigment epithelium (RPE) appears normal. INLp inner nuclear layer; OS/ISp outer segment/inner segment
of the receptor layer. Magnification 40#. C and D, Toluidine blue–stained cross section of cornea from Mcoln1/ mice (C) and
Mcoln1/ mice (D) showing five distinct layers: epithelium (I), Bowman’s layer (II), stroma (III), Descemet’s layer (IV), and endothelium
(V). No storage bodies or architectural differences in stromal keratinocytes between Mcoln1/ and Mcoln1/ mice were noted. Mag-
nification 40#.
Despite this, we do see dramatic retinal degeneration in
the MLIV mouse model that is similar to that described
in patients. The mice show defects in the outer nuclear
layer, the outer plexiform layer, and the inner nuclear
layer. These specific defects, in addition to optic-nerve pal-
lor, are clinically present in patients with MLIV.49,65,66 It is
likely that defective cell signaling leads to increased ap-
optosis in the Mcoln1/ retina, but further studies to de-
termine whether the observed defects are the result of
progressive degeneration, instead of developmental dys-
plasia, will be necessary.
The Mcoln1/ mouse demonstrates a dramatic physical
decline toward the later months of disease that is more
severe than is the human correlate. This may be, in part,
because of the palliation of the disease course in patients
affected with MLIV who receive wheelchair assistance and
other direct interventions. The availability of murine
models is crucial for the development of potential ther-
apies. Proven treatments for LSDs include bone marrow
transplantation, somatic gene therapy, and direct enzyme
replacement.67–70 Recent developments in potential treat-
ment modalities by use of mouse models include herpes
simplex virus type 1 vectors expressing b-glucuronidase
for MPS VII (MIM 253220),71 AAV2/8-mediated gene de-
livery for MPS II (MIM 309900),72 and injection of recom-
binant human sulfamidase into the cerebrospinal fluid of
MPS IIIA mice.73 Small-molecule therapy has also been
pioneered for lysosomal diseases—for example, Niemann-
Pick disease, type C (NPC [MIM 257220])—by use of
mouse models.44 Recent studies have shown that treat-
ment of MLIV fibroblasts with chloroquine or nigericin
can reverse the lysosomal storage phenotype,28 a poten-
tially exciting finding that can now be easily tested for in
vivo efficacy in the MLIV mouse model.
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In conclusion, we present the first murine model for
MLIV. The Mcoln1/ mice show dense granulomembran-
ous storage bodies in neurons that are similar to those
described in patients with MLIV yet are unique from other
LSDs. Other remarkable findings include neurological def-
icits, dramatically elevated plasma gastrin, vacuolization
in the gastric mucosa, and retinal degeneration. Although
the mice appear grossly normal at birth, they show weak-
ness by age 3 mo, and the neurological deficits progress
to complete hind-limb paralysis and death by age ∼8 mo.
This model will provide access to otherwise unattainable
tissues and cell types for future studies of TRPML1 func-
tion, which may help clarify its crucial role in lysosomal
function. Lastly, as has already been proven for other
LSDs, the Mcoln1/ mice will be crucial for the develop-
ment and testing of potential therapeutic agents aimed at
improving patient outcomes in the future.
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